Genotoxicity analysis of the phenoxy herbicide dicamba in mammalian cells in vitro

Toxicol In Vitro. 2006 Dec;20(8):1481-7. doi: 10.1016/j.tiv.2006.05.001. Epub 2006 May 11.

Abstract

The cytogenetic effects exerted by the phenoxy herbicide dicamba and one of its commercial formulations banvel (57.71% dicamba) were studied in in vitro whole blood human lymphocyte cultures. The genotoxicity of herbicides was measured by analysis of the frequency of sister chromatid exchanges (SCEs) and cell-cycle progression assays. Both dicamba and banvel activities were tested within 10.0-500.0 microg/ml doses range. Only concentrations of 200.0 microg/ml of dicamba and 500.0 microg/ml of banvel induced a significant increase in SCE frequency over control values. The highest dose of dicamba tested (500.0 microg/ml) resulted in cell culture cytotoxicity. The cell-cycle kinetics was affected by both test compounds since a significant delay in cell-cycle progression and a significant reduction of the proliferative rate index were observed after the treatment with 100.0 and 200.0 microg/ml of dicamba and 200.0 and 500.0 microg/ml of banvel. For both chemicals, a progressive dose-related inhibition of the mitotic activity of cultures was observed. Moreover, only the mitotic activity statistically differed from control values when doses of both chemicals higher than 100.0 microg/ml were employed. On the basis of our results, the herbicide dicamba is a DNA damage agent and should be considered as a potentially hazardous compound to humans.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Azure Stains
  • Cell Cycle / drug effects
  • Cell Line
  • Cell Proliferation / drug effects
  • Dicamba / toxicity*
  • Dose-Response Relationship, Drug
  • Fluorescent Dyes
  • Herbicides / toxicity*
  • Humans
  • Lymphocytes / drug effects
  • Male
  • Mitotic Index
  • Mutagens*
  • Sister Chromatid Exchange / drug effects

Substances

  • Azure Stains
  • Fluorescent Dyes
  • Herbicides
  • Mutagens
  • Dicamba